Compounds and compositions as protein kinase inhibitors

A compound of Formula I:

• in which:
• m and n are independently selected from 0, 1 and 2;
• R1 is selected from —XNR5R6, —XOR5, —XC(O)R5, —XR5 and —XS(O)0-2R5;
• wherein X is a bond or C1-4alkylene optionally substituted by 1 to 2 C1-6alkyl radicals;
• R5 is selected from hydrogen, C1-6alkyl, C1-10aryl-C0-4alkyl, C5-10heteroaryl-C0-4alkyl, C3-10cycloalkyl-C0-4alkyl and C3-10heterocycloalkyl-C0-4alkyl;
• and R6 is selected from hydrogen and C1-6alkyl;
• or R5 and R6 together with the nitrogen to which R5 and R6 are both attached form heteroaryl or heterocycloalkyl;
• wherein any aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R5 or the combination of R5 and R6 can be optionally substituted with 1 to 3 radicals independently selected from halo, nitro, cyano, hydroxy, C1-6alkyl, C1-6alkoxy, halo-substituted-alkyl, halo-substituted-alkoxy, —XNR7R8, —XOR7, —XNR7S(O)2R8, —XNR7S(O)R8, —XNR7SR8, —XC(O)NR7R8, —XC(O)NR7XNR7R8, —XNR7C(O)NR7R8, —XNR7XNR7R8, —XNR7XOR7, —XNR7C(═NR7)NR7R8, —XS(O)2R9, —XNR7C(O)R8, —XNR7C(O)R9, —XR9, —XC(O)OR8, —XS(O)2NR7R8, —XS(O)NR7R8 and —XSNR7R8;
• wherein X is a bond or C1-4alkylene;
• R7 and R8 are independently selected from the group consisting of hydrogen and C1-4alkyl;
• and R9 is selected from C3-10heterocycloalkyl and C5-10heteroaryl;
• wherein said heterocycloalkyl or heteroaryl of R9 is optionally substituted with a radical selected from the group consisting of C1-4alkyl, —XNR7XNR7R7, XNR7XOR7 and —XOR7;
• R2 and R4 are independently selected from halo, hydroxy, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl and halo-substituted-C1-4alkoxy;
• R3 is selected from —NR10R11, —NR10C(O)R11, —NR10S(O)0-2R11 and —NR10C(O)NR10R11;
• wherein R10 is selected from hydrogen and C1-6alkyl;
• R11 is selected from C6-10aryl, C5-10heteroaryl, C3-10cycloalkyl and C3-10heterocycloalkyl;
• wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R11 is optionally substituted by 1 to 3 radicals selected from halo, nitro, cyano, hydroxy, C1-6alkyl, C1-6alkoxy, halo-substituted-alkyl, halo-substituted-alkoxy, —NR12C(O)R13, —NR12C(O)NR12R13, —C(O)NR12R13, —NR12S(O)0-2R13 and —S(O)0-2NR12R13;
• wherein R12 is selected from hydrogen and C1-6alkyl;
• R13 is selected from C6-10aryl, C5-10heteroaryl, C3-10cycloalkyl and C3-10heterocycloalkyl;
• wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R13 is optionally substituted with 1 to 3 radicals independently selected from halo, C1-6alkyl, halo-substituted-C1-6alkyl, C1-6alkoxy, halo-substituted-C1-6alkoxy, —XNR7R8, C6-10aryl-C0-4alkyl, C5-10heteroaryl-C0-4alkyl, C3-10cycloalkyl-C0-4alkyl, C3-10heterocycloalkyl-C0-4alkoxy and C3-10heterocycloalkyl-C0-4alkyl;
• wherein X, R7 and R8 are as described above and wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl substituent of R13 is further optionally substituted by 1 to 3 radicals independently selected from halo, C1-6alkyl, halo-substituted-C1-6alkyl, hydroxy-substituted-C1-6alkyl, C1-6alkoxy, C3-10heterocycloalkyl and halo-substituted-C1-6alkoxy;
• and the pharmaceutically acceptable salts and stereoisomers thereof.